Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-label, Long-term Extension Safety Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis (EXPEDITION OLE)

NCT04277546 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04277546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04277546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-label, Long-term Extension Safety Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis (EXPEDITION OLE)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
March 3, 2020
Completion date
October 10, 2023
Enrollment
57 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis